Gene therapy development for AP-4 HSPs

Manufacturing collaboration announced

Charles River Laboratories and Cure AP-4 will collaborate on manufacturing gene therapy delivery mechanisms (called plasmids) for pre-clinical investigations on AP-4 Hereditary Spastic Paraplegias.

Charles River Laboratories and Cure AP-4, a non-profit foundation dedicated to raising funds and awareness about adapter-protein 4 Hereditary Spastic Paraplegias (AP-4 HSPs include SPGs 47, 48, 50, 51 & 52) announced a manufacturing collaboration on 6 Sept. 2022 .

Under the collaboration, Charles River will provide high quality (HQ) plasmid DNA for Cure AP-4’s Phase I/II gene therapy trials against AP-4 HSP. DNA plasmids are a critical starting material for many cell and gene therapy therapeutics, and demand continues to exceed supply. To address these supply shortages and support the growing needs of the cell and gene therapy field, Charles River has opened its new HQ plasmid DNA Center located in Cheshire, United Kingdom.

Read more:

SOURCE: BioPharm International Editors. September 9, 2022

Charles River and Cure AP-4 Announce Manufacturing Collaboration

Your email address will not be published. Required fields are marked *